Table 2.
Univariate and multivariate analysis for progression-free survival.
| Characteristics | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Age | ||||||
| <60 | 1 | |||||
| ≥60 | 1.618 | 0.532–4.920 | 0.396 | |||
| Sex | ||||||
| female | 1 | 1 | ||||
| male | 0.852 | 0.195–3.717 | 0.831 | 1.618 | 0.321–8.155 | 0.560 |
| Pathology | ||||||
| WHO I, II | 1 | 1 | ||||
| WHO III | 1.023 | 0.363–2.879 | 0.966 | 1.257 | 0.381–4.143 | 0.707 |
| T stage | ||||||
| I–II | 1 | 1 | ||||
| III–IV | 1.358 | 0.539–3.425 | 0.516 | 1.267 | 0.437–3.672 | 0.663 |
| N stage | ||||||
| 0–I | 1 | 1 | ||||
| II–III | 3.995 | 1.539–10.374 | 0.004 * | 6.912 | 1.877–25.456 | 0.004 * |
| Radiation modality | ||||||
| VMAT | 1 | 1 | ||||
| IMPT | 0.372 | 0.122–1.133 | 0.082 | 0.298 | 0.088–1.011 | 0.052 |
| EBV titer | ||||||
| ≥200 | 1 | 1 | ||||
| <200 | 0.447 | 0.059–3.362 | 0.434 | 0.326 | 0.075–1.409 | 0.133 |
| Induction chemotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 2.679 | 0.952–7.541 | 0.062 | 2.235 | 0.669–7.466 | 0.191 |
| Smoking at diagnosis | ||||||
| No | 1 | 1 | ||||
| Yes | 1.933 | 0.749–4.988 | 0.173 | 2.484 | 0.886–6.912 | 0.084 |
| Weight loss ≥7% | ||||||
| No | 1 | 1 | ||||
| Yes | 2.952 | 1.052–8.283 | 0.040 * | 3.216 | 1.062–9.742 | 0.039 * |
| Nasogastric tube insertion | ||||||
| No | 1 | 1 | ||||
| Yes | 0.631 | 0.144–2.759 | 0.541 | 0.566 | 0.121–2.644 | 0.470 |
| Charlson Comorbidity Index | ||||||
| 0–1 | 1 | 1 | ||||
| ≥2 | 1.383 | 0.455–4.205 | 0.567 | 1.927 | 0.601–6.180 | 0.270 |
| Cisplatin total dose (mg/m2) | ||||||
| <200 | 1 | 1 | ||||
| ≥200 | 0.367 | 0.049–2743 | 0.328 | 0.318 | 0.038–2.660 | 0.290 |
Abbreviations: OR—Odds ratio, CI—Confidence interval, IMPT—Intensity-modulated proton therapy, VMAT—Volumetric modulated arc therapy, EBV—Epstein–Barr virus, WHO—World Health Organization; * means statistically significant.